UNASSIGNED: Increased risk of @entity64 in @entity6 cannot be fully explained by traditional risk factors. Epidemiological studies show that postprandial @entity4854 is strongly associated with cerebrovascular events and cerebrovascular-associated mortality. @entity4854 contributes to @entity1504 by several mechanisms such as @entity409 , arthrosclerosis, oxidative stress, @entity32 , and @entity49 . @entity4854 has deleterious effects on the vascular endothelium and leads to the development of @entity66 . Thus, an important strategy to reduce cerebrovascular risk in @entity1 with @entity6 is to reduce postprandial @entity4854 . Glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and a-glucosidase inhibitors predominantly reduce postprandial plasma @entity413 levels. Among all of these, a-glucosidase inhibitors reduces postprandial @entity4854 by delaying @entity1735 absorption from the intestine and this mechanism provides glycemic control without exacerbating coexisting cerebrovascular risk factors. Good glycemic control is proven to reduce the risk of @entity65 , but equivalent evidence for cerebrovascular risk reduction is lacking. This review examines the evidences that postprandial @entity4854 plays a major role in @entity1504 , along with the complex interplay between @entity4854 and coexisting risk factors. Furthermore, the mechanism by which a-glucosidase inhibitors may prevent this @entity1504 as well as risk of @entity4053 with a-glucosidase inhibitors are examined. Thus, this review suggests that a-glucosidase inhibitors are useful in reducing the risk of cerebrovascular events in @entity1 with @entity6 .

Cerebrovascular Complications of XXXX : Alpha Glucosidase Inhibitor as Potential Therapy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity64 :: ('MESH:D020521', 'Disease') :: ['cerebrovascular accident'] @entity66 :: ('MESH:D004194', 'Disease') :: ['cerebrovascular disease'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction'] @entity49 :: ('MESH:D019851', 'Disease') :: ['hypercoagulability'] @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate'] @entity1504 :: ('MESH:D002561', 'Disease') :: ['vascular damage'] @entity4053 :: ('MESH:D007003', 'Disease') :: ['hypoglycemia'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular complications'] @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia', 'Hyperglycemia', 'Postprandial hyperglycemia'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity6 :: (MESH:D003920,Disease) :: ['Diabetes']
